Nasdaq

Final Phase 2 Data Show Durability of Response for Casdozokitug in Combination with ...

Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...